Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients
Summary
- Most common reasons to modify a virologically suppressive boosted PI–containing regimen are gastrointestinal adverse effects (nausea and diarrhea), high cardiovascular risk, dyslipidemia, pharmacologic interactions with ritonavir, and regimen simplification (less-frequent dosing, lower pill burden) Switching From a Ritonavir-Boosted PI to Rilpivirine
- This switch indication for emtricitabine/rilpivirine/tenofovir DF was based on results from the SPIRIT trial, a randomized, open-label, noninferiority phase IIIb study in which virologically suppressed patients were switched from ritonavir-boosted PI–based regimens to the single-tablet regimen of emtricitabine/rilpivirine/tenofovir DF and evaluated over a 48-week period[Palella 2014]
- Patients were randomized to switch immediately or delay the treatment switch for 24 weeks. The single-tablet regimen was noninferior to continued boosted PI–based therapy based on a Week 24 FDA Snapshot analysis, and 89.3% of patients in the immediate switch arm maintained virologic suppression (< 50 copies/mL) after 48 weeks of therapy
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content